Biotechnology News ACZONE Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-11 out of 11 found

Current Search: aczone: 11

Allergan acquires Aczone gel from QLT
As previously announced, Allergan paid approximately $150 million for all assets relating to Aczone gel 5%.

Allergan expects to launch Aczone gel 5% in the fourth quarter of 2008 in the US and Canada.

David Pyott, chairman of...

Pharmaceutical Business Review: Jul 16 2008 5:41AM
Matching: aczone

Find similar documents

Allergan purchases Aczone from QLT
_ Allergan purchases Aczone from QLT.

Drug Store News: Jul 16 2008 10:30PM
Matching: aczone

Find similar documents

QLT offloads acne drug in US$150 million deal as Vancouver biotech continues restructuring
QLT Inc.

(TSX:QLT; Nasdaq:QLTI) has sold its Aczone topical acne treatment to a subsidiary of California-based Allergan Inc.

for US$150 million.

The deal is part of the Vancouver biotech's sale of non-core assets as it...

Business in Vancouver: Jul 16 2008 10:28AM
Matching: aczone

Find similar documents

Allergan acquires Aczone gel from QLT
Allergan Sales, a wholly-owned subsidiary of Allergan, and QLT USA, a wholly-owned subsidiary of QLT, have announced the completion of Allergan's acquisition of QLT's Aczone gel 5% product, a topical treatment for acne vulgaris.As...

Datamonitor: Jul 15 2008 8:12PM
Matching: aczone

Find similar documents

QLT Completes Divestment of Aczone to Allergan for USD$150 Million
/PRNewswire-FirstCall/ - QLT Inc.

today announced that QLT USA, Inc., its wholly-owned subsidiary, completed the sale of its Aczone(R) (dapsone) Gel 5% product, a topical treatment for acne vulgaris, to Allergan Sales, LLC, a wholly-owned...

Pharma Live: Jul 15 2008 3:09PM
Matching: aczone

Find similar documents

Allergan Completes Acquisition of Aczone Gel 5%
- Allergan, Inc.'s (NYSE:AGN) wholly-owned subsidiary, Allergan Sales, LLC, and QLT USA, Inc., a wholly-owned subsidiary of QLT Inc.

(NASDAQ:QLTI) (TSX:QLT) today announced the completion of Allergan's acquisition of QLT's Aczone(R) ...

Pharma Live: Jul 14 2008 3:09PM
Matching: aczone

Find similar documents

FDA MedWatch - March 2008 Safety-Related Labeling Changes Posted
-The March 2008 posting includes 50 drug products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and PATIENT PACKAGE INSERTS, and MEDICATION ES.

The...

Pharma Live: Jul 1 2008 5:54PM
Matching: aczone

Find similar documents

Allergan to acquire QLT's Aczone gel 5%
Allergan, Inc.

announced that its wholly-owned subsidiary, Allergan Sales, LLC, has entered into an agreement with QLT USA, Inc., a wholly-owned subsidiary of QLT Inc., to acquire QLT's Aczone (dapsone) gel 5 per cent product, a...

PharmaBiz: Jun 14 2008 12:30PM
Matching: aczone

Find similar documents

Allergan buys QLT's acne drug
Under the terms of the agreement, QLT will receive a one-time cash payment of approximately $150 million upon closing, which is expected to occur in the third quarter of 2008.

The transaction has been approved by the board of directors of...

Pharmaceutical Business Review: Jun 11 2008 4:40AM
Matching: aczone

Find similar documents

QLT Announces Agreement to Sell Aczone to Allergan for Approximately US$150 Million
/PRNewswire-FirstCall/ - QLT Inc.

announced today that QLT USA, Inc., its wholly-owned subsidiary, has entered into an asset purchase agreement with Allergan Sales, LLC, a wholly-owned subsidiary of Allergan, Inc.

to fully divest QLT's...

Pharma Live: Jun 9 2008 11:53AM
Matching: aczone

Find similar documents

Allergan Announces Agreement to Acquire Aczone Gel 5%
- Allergan, Inc.

(NYSE:AGN) today announced that its wholly-owned subsidiary, Allergan Sales, LLC, has entered into an agreement with QLT USA, Inc., a wholly-owned subsidiary of QLT Inc.

(NASDAQ:QLTI) (TSX:QLT), to acquire QLT's Aczone(R...

Pharma Live: Jun 9 2008 12:03PM
Matching: aczone

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.